EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Klinische Studie (Phase II)

Nowarta110 Topical Versus Placebo for the Treatment of Plantar Warts: A Phase I/II Randomized Controlled Clinical Trial

Mahkameh Yousefpour, Iraj Zamanian, Ferre Akbarpour, William H Fang, B O Han, Ba X Hoang

Anticancer Research · 2023

DOI: 10.21873/anticanres.16363 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Anticancer Research, 2023. Verfasst von Mahkameh Yousefpour und 5 weiteren Autor:innen. Beteiligte Einrichtung: Orange County Foot Clinic, Fullerton, CA, U.S.A. Hauptthemen laut MEDLINE: Papillomavirus Infections, Warts, Foot Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Plantar warts are cutaneous lesions on the plantar aspect of the foot caused by the infection of keratinocytes with the human papillomavirus (HPV). The severity and magnitude of warts can vary, but they cause pain and discomfort for all age groups. The treatment for plantar warts remains a continuing challenge. The purpose of this research was to compare the efficacy and safety of naturally derived Nowarta110 topical formula versus a matching placebo in treating plantar warts. PATIENTS AND METHODS: The study is a randomized, double-blind, parallel assignment control interventional phase I/II clinical trial. This study included 54 patients with plantar warts. Patients were randomized to two groups: the placebo group, which included 26 patients treated with a matching placebo and the Nowarta110 group, which included 28 patients who received topical Nowarta110. The diagnosis of plantar warts was made by clinical examination. The treatment's efficacy and safety were assessed every week and after 6 weeks from the initiation of the intervention. RESULTS: In the Nowata110 group, 18 patients (64.3%) were completely cleared of their warts, and 10 patients (35.7%) partially responded to the therapy with a 20% to 80% decrease in warts dimensions. In the placebo group, only 2 patients (7.7%) were completely cleared of their warts, and 3 patients (11.5%) partially responded to the intervention with a 10% to 35% decrease in warts dimensions. The difference was highly significant between the two groups. There was 1 event with minor pain as a side effect in the Nowarta110 group and 9 events of non-serious local side effects in the placebo group, which included 2 patients who dropped out. CONCLUSION: Topical Nowarta110 is a safe, well-tolerated, and highly effective therapeutic modality in treating refractory and recurrent plantar warts. The breakthrough findings of the study encourage further extensive clinical trials to fully explore the prospect of Nowarta110 in managing all types of warts and HPV-related diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsWartsFoot DiseasesHumansFootPainTreatment Outcome

Stichwörter der Autor:innen

HPVWartsphytotherapyplantar warttopical treatmentviral infections

Autor:innen und Institutionen

  • Orange County Foot Clinic, Fullerton, CA, U.S.A.
  • Palm View Medical, Irvine, CA, U.S.A.
  • Orange County Immune Institute, Newport Beach, CA, U.S.A.
  • Department of Translational Research, Western University of Health Sciences, Pomona, CA, U.S.A.
  • Nimni-Cordoba Tissue Engineering and Drug Discovery Lab, Department of Surgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, U.S.A.
  • Nimni-Cordoba Tissue Engineering and Drug Discovery Lab, Department of Surgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, U.S.A. baxuanho@usc.edu.

Zitieren

APA

Yousefpour, M., Zamanian, I., Akbarpour, F., Fang, W. H., Han, B. O., & Hoang, B. X. (2023). Nowarta110 Topical Versus Placebo for the Treatment of Plantar Warts: A Phase I/II Randomized Controlled Clinical Trial. Anticancer Research. https://doi.org/10.21873/anticanres.16363

Vancouver

Yousefpour M, Zamanian I, Akbarpour F, Fang WH, Han BO, Hoang BX. Nowarta110 Topical Versus Placebo for the Treatment of Plantar Warts: A Phase I/II Randomized Controlled Clinical Trial. Anticancer Research. 2023. doi:10.21873/anticanres.16363

BibTeX
@article{Yousefpour2023,
  author = {Yousefpour, Mahkameh and Zamanian, Iraj and Akbarpour, Ferre and Fang, William H and Han, B O and Hoang, Ba X},
  title = {Nowarta110 Topical Versus Placebo for the Treatment of Plantar Warts: A Phase I/II Randomized Controlled Clinical Trial},
  journal = {Anticancer Research},
  year = {2023},
  doi = {10.21873/anticanres.16363}
}
Kostenlos starten →